Machine learning links circulating tyrosine and distinct lipid-metabolite features to diabetic kidney disease and retinopathy detection
In 2,772 adults with diabetes from Singapore’s population-based SEED study, LASSO and gradient-boosting models screened 220 circulating metabolites and 19 clinical factors for prevalent diabetic kidney disease (DKD) and retinopathy (DR), then were externally assessed in 5,843 UK Biobank participants. Both outcomes shared diabetes duration, insulin use, age and tyrosine as important model features. DKD additionally selected cardiovascular disease history, antihypertensive use, lactate, citrate and the intermediate-density-lipoprotein cholesterol-ester/total-lipid ratio; DR additionally selected HbA1c, glucose, pulse pressure and alanine. External AUCs were 0.791 for DKD and 0.778 for DR, versus 0.691 and 0.760 for conventional adjusted logistic-regression comparators.
Technology: Least absolute shrinkage and selection operator logistic regression and gradient-boosting decision trees applied to metabolomics and clinical risk factors
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In 2,772 adults with diabetes from Singapore’s population-based SEED study, LASSO and gradient-boosting models screened 220 circulating metabolites and 19 clinical factors for prevalent diabetic kidney disease (DKD) and retinopathy (DR), then were externally assessed in 5,843 UK Biobank participants.
- Still unknown: The analysis is retrospective and cross-sectional; it classifies prevalent complications and cannot establish temporal prediction or causal effects of tyrosine, lactate, citrate, alanine or lipid features. The Singapore cohort was recruited in 2004–2011 and was multiethnic Asian; about 95% had type 2 diabetes, but the study did not separate diabetes types. UK Biobank definitions and available eye-severity measures differed, and validation of moderate-or-worse DR was not feasible. Performance is modest, particularly external AUC 0.791 DKD/0.778 DR, and does not establish clinical utility.
- AI role: ML feature selection prioritized a shared set of clinical/metabolic factors and distinct DKD- and DR-associated metabolites, then built detection models externally evaluated in UK Biobank. These models outperformed traditional adjusted logistic-regression comparators in the reported internal and external validation. The scientific result is the disease-specific feature pattern and its validated detection performance, not merely an algorithm benchmark.
Evidence sources: https://www.jmir.org/2024/1/e41065/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 10% of works of the same type, year and subfield (OpenAlex work metrics, 30 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.